Purpose: In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole
It can be used as an adjuvant for the early stage 1 or a palliative for the advanced disease
Your specialist may suggest changing to a different aromatase inhibitor such as letrozole or exemestane, Some people benefit from switching to a different hormone therapy
This activity will highlight the mechanism of action
The third-generation aromatase inhibitors (AIs), including anastrozole, exemestane and letrozole, have demonstrated improved efficacy versus tamoxifen for the adjuvant endocrine treatment of postmenopausal patients with hormone receptor-positive breast cancer
AIs can be used in several adjuvant endocrine settings: as upfront
After 3 months of exemestane, CT showed that all lung metastases had completely resolved
29% of reviewers reported a positive effect, while 37% reported a negative effect
Exemestane (ex" e mes' tane) is an aromatase inhibitor that acts as an antiestrogen and is used to treat postmenopausal women with estrogen receptor positive breast cancer
If you tank your estrogen though it'll take longer to come back